Clinical trial
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 75 mg and 150 mg Doses of ERB-041 on the Reduction of Symptoms Associated With Endometriosis During Treatment and Post Treatment in Reproductive-Aged Women
NCT00318500 is registered in ClinicalTrials.gov with Wyeth is now a wholly owned subsidiary of Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 75 mg and 150 mg Doses of ERB-041 on the Reduction of Symptoms Associated With Endometriosis During Treatment and Post Treatment in Reproductive-Aged Women
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 31, 2006
- Completion date
- December 31, 2006
- Enrollment
- 150
- Sites
- 70
Conditions
As the registry lists them; a condition with its own page is linked.